Eli Lilly and Company (NYSE:LLY) is at least 36.14% than its current record low price of $84.64. There was a 0.51% gain on 6/19/2019 that led the price to move at $115.23. At a recent session, the prices were hovering between $114.34 and $115.99. This company shares are 8.23% off its target price of $124.71 and the current market capitalization stands at $111.95B. The recent change has given its price a -1.85% deficit over SMA 50 and -12.79% deficit over its 52-week high. The stock witnessed -0.86% declines, -10.09% declines and 6.34% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found LLY’s volatility during a week at 2.04% and during a month it has been found around 1.76%.
What Does Eli Lilly and Company (LLY) Do?
The company describes itself in regulatory filings as, “Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through the following segments: Human Pharmaceutical Products and Animal Health Products. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other. The Animal health Products segment operating through the Elanco Animal Health division, develops, manufactures, and markets products for both food and companion animals. The Animal health products include Rumensin, Tylan, Posilac, Paylean and other products for livestock and poultry, as well as Trifexis, Comfortis, and other products for companion animals. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.” [Text can be found here: https://www.marketwatch.com/investing/stock/LLY/profile under company description.]Eli Lilly and Company (LLY) Top Holders
Institutional investors currently hold around $89.5 billion or 83.2% in LLY stock. Look at its top three institutional owners: Lilly Endowment Inc owns $13.39 billion in Eli Lilly and Company, which represents roughly 11.96% of the company’s market cap and approximately 14.96% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 70,556,333 shares of the stock are valued at $8.09 billion. The third largest holder is Blackrock Inc., which currently holds $7 billion worth of this stock and that ownership represents nearly 6.26% of its market capitalization.
At the end of March reporting period, 587 institutional holders increased their position in Eli Lilly and Company (NYSE:LLY) by some 31,890,331 shares, 851 decreased positions by 76,119,290 and 254 held positions by 672,660,692. That puts total institutional holdings at 780,670,313 shares, according to SEC filings. The stock grabbed 147 new institutional investments totaling 2,453,991 shares while 107 institutional investors sold out their entire positions totaling 2,499,370 shares.Eli Lilly and Company (NYSE:LLY) Insider Trades
Multiple company employees have indulged in significant insider trading. Eli Lilly and Company disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP and CFO Smiley Joshua L has acquired 426 shares of Eli Lilly and Company (LLY) in the trading session dated Jun. 05, 2019. These shares are worth $50,281 and were traded at $118.03 each. The SEC filing shows that Harrington Michael J performed a sale of 16,000 shares. The Senior VP and General Counsel disposed these shares by way of transaction on Jun. 03, 2019. The company’s shares were given away at $116.72 per share worth to an income of some $1,867,520 to the account of Harrington Michael J.
SVP and Pres., Lilly Bio-Meds, Shaw Christi, sold 7,577 common shares of Eli Lilly and Company (LLY) in the open market. In a transaction dated May. 03, 2019, the shares were put up for sale at an average price of $117.14, raking in a sum of $887,570. After this sale, common shares of LLY are directly owned by the insider, with total stake valued at $.
In the transaction dated May. 03, 2019, a great number of shares sold came courtesy the SVP and Pres., Lilly Bio-Meds; Shaw Christi disposed a total of 7,077 shares at an average price of $117.08, amounting to approximately $828,575. The insider now directly owns 500 shares worth $57,615.Eli Lilly and Company (LLY) Analyst Guide
Several analysts have released their opinion on Eli Lilly and Company (NYSE:LLY), with 2 analysts believing it is a strong buy. Whereas 9 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.44 average brokerage recommendation [T1].